Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Puja.Sharma@globaldata.com

  • Home
  • Author: Puja.Sharma@globaldata.com

Nightstar acquisition will catapult Biogen in global ophthalmology market, says GlobalData

Following the news on 4th March 2019 that US-based biotechnology company, Biogen, has agreed to acquire London-based clinical-stage gene therapy company, Nightstar Therapeutics, which is focused on adeno-associated virus treatments for inherited retinal disorders, for approximately $800m, Maura Musciacco, MSc, Neurology & Ophthalmology Director at GlobalData, offers her view: “Biogen continues its diversification strategy through […]
Read more

M&A volume surges while VC funding count fluctuates in payment tech space between 2014 and 2018, says GlobalData

The payment technologies space witnessed a consistent growth in M&A volume between 2014 and 2018; however, venture capital (VC) funding fluctuated during the same period, according to GlobalData, a leading data and analytics company. M&A volume increased at a compound annual growth rate (CAGR) of 35.1% during the review period, with growth witnessed across all […]
Read more

Swiggy’s grocery delivery service Stores likely to face stiff competition in India, says GlobalData

Following the recent announcement that Naspers-backed India-based food-delivery start-up Swiggy is foraying into on-demand product deliveries across categories with concierge-like service ‘Swiggy Stores’ in Gurugram, a city just southwest of national capital New Delhi, Shagun Sachdeva, Consumer Insights Analyst at GlobalData, a leading data and analytics company, offers her view: “Swiggy, which in December 2018 […]
Read more

Kellogg’s eyes Indian snacks giant Haldiram’s to diversify beyond core breakfast cereal category, says GlobalData

Following the news that breakfast cereal behemoth Kellogg’s is in discussions to buy a 51% stake in two divisions of India-based snack maker Haldiram’s for US$3bn, Sumit Chopra, Consumer Research Director at GlobalData, a leading data and analytics company, offers his views: “Kellogg’s has been scouting for opportunities to foray into the traditional sweets & […]
Read more

Major economies set for moderate slowdown in 2019, says GlobalData

Major global economies, including the US, the EU region, Indonesia, Russia and China, are set for a moderate slowdown in 2019 owing to uncertainties related to the protectionist policies advocated by various national governments, lower levels of consumer confidence and high levels of national debts, according to GlobalData, a leading data and analytics company. Financial […]
Read more

AI attracts largest number of investors while payments technology commands highest investors-to-idea ratio, finds GlobalData

Among all emerging technologies, artificial intelligence (AI) has attracted the largest number of investors during 2018, according to GlobalData, a leading and data analytics company. With an increasing application of AI technologies across industries, more than 1,900 investors funded 1,000 AI-based companies in 2018. Some of the key funded companies working in the AI space […]
Read more

Patient coverage under P4P model for Pfizer’s Ibrance limited in current phase, says GlobalData

Pfizer, in collaboration with Shanghai Branch of PICC Health Insurance and the Shanghai MediTrust Health, launched China’s first pay-for-performance (P4P) model featuring its blockbuster breast cancer drug Ibrance – ‘Bo’ai Xin’an – Patient Benefit Management Program’ – in late January 2019. Against this backdrop, Prashant Khadayate, Pharma Analyst at GlobalData, offers his view on Pfizer’s […]
Read more

Asia will drive global economy in 2019, says GlobalData

Asia will drive the global economy in 2019, according to an analysis of 40 major economies based on inflation and GDP growth forecasts by GlobalData, a leading data and analytics company. The company’s analysis categorizes each country by ‘Low’, ‘Moderate’ and ‘High’ GDP growth rate together with ‘High Inflationary Economies’ during the period 2014-2018 (annual […]
Read more

Despite Phase III failure, Gilead’s selonsertib may still have place in NASH combination therapy strategy, says GlobalData

Despite its failure in the Phase III STELLAR-4 trial, Gilead Sciences’ lead non-alcoholic steatohepatitis (NASH) drug candidate, selonsertib, may still have a place in NASH combination therapy strategy, according to GlobalData, a leading data and analytics company. On 11 February 2019, the American biotechnology giant announced that selonsertib did not meet its primary endpoint in […]
Read more
1 … 5 6 7 8 9